AstraZeneca new boss's debut buy
AstraZeneca's new boss yesterday agreed his first major deal at the pharmaceuticals giant, spending up to $272m (£169m) on the rights to an experimental kidney drug. This month, on his first day in the job, Pascal Soriot suspended Astra's share buybacks for the rest of the year.
Now the drug maker, which is suffering from key medicines running out of patent and a series of failed trials, has bought into a renal treatment, biotech Ardelyx's NHE3 inhibitor programme.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies